John P. Butler
CIK 1591467 · CEO and President · last filed 2026-08-10
John P. Butler is a CEO and President who has filed 60 SEC Form 4 insider transactions across 4 companies since 2013. The most recent filing shows the insider exercised options covering $220.5K of AKBA on Aug 10, 2026. Across all open-market trades the lifetime net is −$1.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions. 6 Form 144 notices of planned sales are also on file; the latest, for AKBA on Feb 2, 2026, lists the filer as an officer.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKBA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
245 FIRST STREET
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKBA | CEO and President | 3,878,492 | $0.42 | $1.65M | -$999.1K | 37 | 2026-08-10 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 0 | $1.30 | $0 | $32.1K | 9 | 2023-10-11 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 20,000 | — | — | $0 | 2 | 2017-06-20 |
| Relypsa Inc (RLYP) Delisted | Director | 0 | — | — | -$57.7K | 6 | 2016-09-02 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| AKBA | Direct | 3,718,564 | 95.9% | 2026-08-10 |
| Held by Dorothy Butler Revocable Trust November 20, 2007 | 159,928 | 4.1% | 2026-08-10 | |
| Total | 3,878,492 | |||
| No longer reported | ||||
| Held by John Butler 2019 GRAT | 59,928 | — | last 2025-03-04 | |
| Held by Dorothy Butler 2019 GRAT | 59,928 | — | last 2025-03-04 | |
| Held By Dorothy Butler GRAT November 2019 | 100,000 | — | last 2025-03-04 | |
| Held By John Butler GRAT November 2019 | 100,000 | — | last 2025-03-04 | |
| Held by Dorothy Butler Revocable Trust 2007 | 31,047 | — | last 2021-04-01 | |
| Held by John Butler Revocable Trust 2007 | 31,047 | — | last 2021-04-01 | |
| Held by John Butler 2016 GRAT | 31,047 | — | last 2020-03-02 | |
| Held by Dorothy Butler 2016 GRAT | 31,047 | — | last 2019-06-05 | |
| Held by John P. Butler Revocable Trust November 20, 2007 | 27,353 | — | last 2019-03-05 | |
Recent Filings
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-10 | AKBA | Exer (M) | +350,000 | $220.5K | EDGAR |
| 2026-03-05 | AKBA | Buy (P) | +69,270 | $86.6K | EDGAR |
| 2026-02-04 | AKBA | Mixed10b5-1 Plan adopted Sep 8, 2025 |
−166,055 | -$227.3K | EDGAR |
| 2026-02-03 | AKBA | Grant (A) | +743,000 | $0 | EDGAR |
| 2026-02-02 | AKBA | Notice (144) Officer · Planned Feb 2, 2026 · 10b5-1 plan Sold: Form 4 filed Feb 4, 2026 |
−341,305 | -$475.9K | EDGAR |
| 2025-03-04 | AKBA | Sell (S)10b5-1 Plan adopted Dec 1, 2023 |
−46,409 | -$84.9K | EDGAR |
| 2025-03-03 | AKBA | Notice (144) Officer, Director · Planned Mar 3, 2025 Sold: Form 4 filed Mar 4, 2025 |
−46,409 | -$85.0K | EDGAR |
| 2025-02-04 | AKBA | Mixed10b5-1 Plan adopted Dec 1, 2023 |
+556,750 | -$302.9K | EDGAR |
| 2025-02-03 | AKBA | Notice (144) Officer, Director · Planned Feb 3, 2025 Sold: Form 4 filed Feb 4, 2025 |
−144,250 | -$303.6K | EDGAR |
| 2024-03-01 | AKBA | Sell (S) | −46,570 | -$73.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).